NASDAQ · Biotechnology · USD

Retension Pharmaceuticals, Inc. (RTSN) Stock Analysis

Retension Pharmaceuticals, Inc. (RTSN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

RTSN

$15.00

−$1.18 (−7.29%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RTSN with… →

RTSN Key Statistics

As of Oct 21, 2026

Trading

Open: $16.18
Previous Close: $16.18
Day's Range: 14.29–18.19
52-Week Range: 9.66–18.64
Volume: 109.96K

Valuation

Market Cap: $124.97M
P/E Ratio: unprofitable
EPS (ttm): −2.61

Financials (FY)

Shares Outstanding: 8.33M

Dividend and dates

Avg Volume: 235.41K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Retension Pharmaceuticals, Inc. (RTSN) has a market capitalization of $124.97M.

Analysis

Data-derived

Company Overview

The market values Retension Pharmaceuticals, Inc. (RTSN) at $124.97M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 12 employees.

RTSN last closed at $15.00 on October 21, 2026. That is −$1.18 (−7.29%) against the previous close. Over the past 52 weeks the price has ranged from $9.66 to $18.64. The latest close sits 55.28% above that 52-week low.

Financial Health

Trailing earnings per share are −2.61.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Growth & Income

No dividend is on file for RTSN.

So far in 2026 the total return is +42.45%.

Peer Comparison

Retension Pharmaceuticals, Inc. (RTSN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Retension Pharmaceuticals, Inc.	RTSN	$124.97M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Retension Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Retension Pharmaceuticals, Inc.

Retension Pharmaceuticals, Inc. operates as a clinical -stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. It offers RTN -001, an oral, small molecule phosphodiesterase -5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling. The Company operates as a single operating and reportable segment focused on the development of treatments for hypertension and cardiovascular disease. The company was incorporated in 2023 and is headquartered in Falls Church, Virginia.

Visit website →